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Résumé en
anglais
Neurodegenerative (ND) complications in Langerhans cell histiocytosis (LCH) are a
late-onset but dramatic sequelae for which incidence and risk factors are not well
defined. Based on a national prospective registry of paediatric LCH patients, we
determined the incidence rate of clinical ND LCH (cND-LCH) and analysed risk
factors, taking into account disease extent and molecular characteristics. Among
1897 LCH patients, 36 (1·9%) were diagnosed with a cND-LCH. The 10-year
cumulative incidence of cND-LCH was 4·1%. cND-LCH typically affected patients
previously treated for a multisystem, risk organ-negative LCH, represented in 69·4%
of cND-LCH cases. Pituitary gland, skin and base skull/orbit bone lesions were more
frequent (P < 0·001) in cND-LCH patients compared to those without cND-LCH
(respectively 86·1% vs. 12·2%, 75·0% vs. 34·2%, and 63·9% vs. 28·4%). The 'cND
susceptible patients' (n = 671) i.e., children who had experienced LCH disease with
pituitary or skull base or orbit bone involvement, had a 10-year cND risk of 7·8% vs.
0% for patients who did not meet these criteria. Finally, BRAF status added
important information among these cND susceptible patients, with the 10-year cND
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